← 返回前沿论文

纳米医学在淋巴瘤精准管理中的进展:机制、诊断与治疗策略

英文原题:Advancements in Nanomedicine for Precision Management of Lymphoma: Mechanisms, Diagnostics, and Therapeutic Strategies.

PubMed 2026/04/22(内容时间) Int J Nanomedicine Q1 · IF 8.7(JCR 2025)

研究概要

淋巴瘤是一种起源于淋巴和造血系统的异质性恶性肿瘤。

中文摘要

淋巴瘤是一种起源于淋巴和造血系统的异质性恶性肿瘤。由于淋巴瘤的复杂性、播散性和耐药性,传统的诊断和治疗方法面临显著局限。因此,需要新的方法来实现精准管理和治疗。近年来,纳米技术的进步为淋巴瘤治疗提供了新的可能性,特别是通过材料科学与生物医学的跨学科研究,为精准治疗提供了有前景的策略。本综述系统总结了纳米医学在淋巴瘤管理中的最新进展。首先,介绍了纳米技术干预的机制,强调淋巴瘤的病理特征。其次,重点介绍了前沿的诊断应用,包括细胞外囊泡检测、高灵敏度核酸生物标志物传感和多模态成像。此外,讨论了新兴的治疗策略,如集诊断、治疗和实时监测于一体的纳米平台。示例包括优化的 mRNA 疫苗递送、增强的嵌合抗原受体(CAR)T 细胞疗法、双特异性纳米颗粒系统以及基因/化疗联合方法。最后,本综述概述了临床转化相关的挑战,并提出了智能自适应纳米医学的未来方向,强调其显著推进淋巴瘤诊断和治疗范式的潜力。

展开英文摘要原文

Lymphoma is a heterogeneous malignancy originating from the lymphatic and hematopoietic systems. Traditional diagnostic and therapeutic approaches face significant limitations due to the complexity, dissemination, and drug resistance associated with lymphoma. Thus, novel approaches are required for precise management and treatment. Recently, advances in nanotechnology have provided new possibilities for lymphoma therapy, particularly through interdisciplinary research combining materials science and biomedicine, thus offering promising strategies for precision treatment. This review systematically summarizes recent advancements in nanomedicine for lymphoma management. First, it introduces mechanisms of nanotechnological interventions, emphasizing lymphoma's pathological features. Next, cutting-edge diagnostic applications, including extracellular vesicle detection, high-sensitivity nucleic acid biomarker sensing, and multimodal imaging, are highlighted. Additionally, emerging therapeutic strategies such as integrated nanoplatforms combining diagnostics, treatment, and real-time monitoring are discussed. Examples include optimized mRNA vaccine delivery, enhanced chimeric antigen receptor (CAR) T-cell therapy, bispecific nanoparticle systems, and combination gene/chemotherapy approaches. Finally, this review outlines the challenges associated with clinical translation and suggests future directions for intelligent adaptive nanomedicine, emphasizing its potential to significantly advance lymphoma diagnosis and therapeutic paradigms.

论文信息

作者
Wang R、Zhang Z、Wang Q、Gu P、Yang Y、Wang B、Teng Y
第一作者单位
School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan Province, 610550, People's Republic of China.China
通讯作者单位
Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang Province, 310003, People's Republic of China.China
文献类型
综述
期刊
International journal of nanomedicine2026
原文标识
PubMed 42046736 · DOI 10.2147/IJN.S580526